LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

Inicio・Lista de Acciones・Bio-Rad Laboratories Inc

Bio-Rad Laboratories Inc

Cerrado

Sector Salud

322 -2.34

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

318.72

Máximo

330.56

Métricas clave
By Trading Economics
Ingresos	-2.5B -2.2B
Ventas	28M 639M
BPA	3.11
Margen de beneficio	-339.153
Empleados	8,030
EBITDA	-3.3B -2.7B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+14.09 upside

Dividendos
By Dow Jones
Próximas Ganancias	24 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	65M 9.6B
Apertura anterior	324.34
Cierre anterior	322

Noticias sobre sentimiento de mercado

By Acuity

50%

100 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

318.785 / 333.71 Soporte y Resistencia

Bio-Rad Laboratories Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2024, 23:42 UTC

Ganancias

Syrah Resources: Vidalia AAM Facility Has Ramped Up Operations

8 sept 2024, 23:41 UTC

Ganancias

Syrah Resources: No Natural Graphite Shipments in Half-Year to Chinese Anode Customers Amid Competition, Oversupply

8 sept 2024, 23:40 UTC

Ganancias

Syrah Resources: Half-Year Balama Production and Sales Decreased Compared With Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Revenue US$19 Mln Vs US$28.4 Mln in Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Comprehensive Loss US$63.3 Mln Vs US$37.1 Mln Loss in Prior Period

8 sept 2024, 22:38 UTC

Principales Noticias

Stocks Are Poised to Fall -- Barrons.com

8 sept 2024, 18:40 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- Update

8 sept 2024, 15:24 UTC

Principales Noticias

Boeing Reaches Deal With Biggest Union in Effort to Avoid Strike -- WSJ

8 sept 2024, 13:00 UTC

Principales Noticias

Crypto Plan Creates Potential Conflicts for Trump -- WSJ

8 sept 2024, 09:00 UTC

Principales Noticias

Nvidia Draws Antitrust Scrutiny as Enforcers Signal Early Interest in AI -- WSJ

8 sept 2024, 07:30 UTC

Principales Noticias

Biotechs Are in Focus as Congress Looks to Get Tougher on China -- Barrons.com

8 sept 2024, 01:00 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- WSJ

7 sept 2024, 17:35 UTC

Principales Noticias

Fed Outlook Remains Uncertain After September Cut -- Barrons.com

7 sept 2024, 09:30 UTC

Principales Noticias

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- Heard on the Street -- WSJ

7 sept 2024, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 sept 2024, 04:05 UTC

Principales Noticias

China's Forex Reserves Rose in August as U.S. Dollar Weakened -- WSJ

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

Comparación entre iguales

Cambio de precio

Bio-Rad Laboratories Inc Esperado

Precio Objetivo

By TipRanks

14.09% repunte

Estimación a 12 meses

Media 376.2 USD 14.09%

Máximo 401 USD

Mínimo 340 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Rad Laboratories Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Bio-Rad Laboratories Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

318.785 / 333.71Soporte y Resistencia

Bullish events outweigh bearish events.

All events are bullish.

Bullish events outweigh bearish events.

Sentimiento

By Acuity

100 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.